- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05335122
A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)
December 11, 2023 updated by: Ocular Therapeutix, Inc.
A Prospective, Multi-center, Randomized, Parallel-group, Controlled Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant in Subjects With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)
To assess efficacy, and safety of a single sustained release dose of the OTX-TIC drug product (2 travoprost dose strengths) in subjects with Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
Study Overview
Status
Active, not recruiting
Conditions
Detailed Description
This is a prospective, multi-center, randomized, parallel-group, controlled study to evaluate the efficacy, and safety of OTX-TIC (travoprost) intracameral implant in subjects with open angle glaucoma (OAG) or ocular hypertension (OHT).
Approximately 105 subjects will be enrolled in this study at approximately 20 sites in the US.
Subjects will be a randomized to one of three treatment groups OTX-TIC drug product (2 travoprost dose strengths) compared to a single injection of DurystaTM.
Non study eyes will be treated with the PGA, if not contraindicated.
Study Type
Interventional
Enrollment (Estimated)
105
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Dothan, Alabama, United States, 36301
- Ocular Therapeutix, Inc.
-
-
California
-
Huntington Beach, California, United States, 92647
- Ocular Therapeutix, Inc.
-
Irvine, California, United States, 92604
- Ocular Therapeutix, Inc.
-
Los Angeles, California, United States, 90013
- Ocular Therapeutix, Inc.
-
Pasadena, California, United States, 91107
- Ocular Therapeutix, Inc.
-
Petaluma, California, United States, 94954
- Ocular Therapeutix, Inc.
-
Redlands, California, United States, 92373
- Ocular Therapeutix, Inc.
-
Torrance, California, United States, 90505
- Ocular Therapeutix, Inc.
-
-
Florida
-
Clearwater, Florida, United States, 33761
- Ocular Therapeutix, Inc.
-
Delray Beach, Florida, United States, 33484
- Ocular Therapeutiux, Inc.
-
Fort Myers, Florida, United States, 33901
- Ocular Therapeutix, Inc.
-
-
Georgia
-
Roswell, Georgia, United States, 30076
- Ocular Therapeutix, Inc.
-
-
Illinois
-
Rock Island, Illinois, United States, 61201
- Ocular Therapeutix, Inc.
-
-
Indiana
-
Carmel, Indiana, United States, 46032
- Ocular Therapeutix Inc
-
-
Michigan
-
Saint Joseph, Michigan, United States, 49085
- Ocular Therapeutix, Inc.
-
-
Missouri
-
Saint Joseph, Missouri, United States, 49085
- Ocular Therapeutix, Inc.
-
Saint Louis, Missouri, United States, 63110
- Ocular Therapeutix Inc.
-
-
New Jersey
-
Dover, New Jersey, United States, 07801
- Ocular Therapeutix, Inc.
-
-
New York
-
Troy, New York, United States, 12108
- Ocular Therapeutix, Inc.
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Ocular Therapeutix, Inc.
-
-
North Dakota
-
Fargo, North Dakota, United States, 58103
- Ocular Therapeutiux, Inc.
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Ocular Therapeutix, Inc.
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
- Ocular Therapeutix Inc
-
-
Pennsylvania
-
Cranberry Township, Pennsylvania, United States, 16066
- Ocular Therapeutix, Inc.
-
Philadelphia, Pennsylvania, United States, 19107
- Ocular Therapeutix, Inc.
-
-
Texas
-
Austin, Texas, United States, 78701
- Ocular Therapeutix, Inc.
-
Dallas, Texas, United States, 75231
- Ocular Therapeutix, Inc.
-
El Paso, Texas, United States, 79902
- Ocular Therapeutix, Inc.
-
Houston, Texas, United States, 77030
- Ocular Therapeutix, Inc.
-
-
Wisconsin
-
Kenosha, Wisconsin, United States, 53142
- Ocular Therapeutix, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Are 18 years of age or older at the time of screening
- Provide written informed consent and are able to comply with all study requirements
- Are willing to withhold glaucoma medications according to the study requirements, and in the opinion of the investigator can do so without significant risk
- Have a negative pregnancy test result for women of childbearing potential at Baseline
- Have a documented diagnosis of OHT, or OAG in the study eye
Exclusion Criteria:
- Have an uncontrolled systemic disease or a debilitating disease (e.g., cardiovascular, hypertension, uncontrolled diabetes)
- Are currently pregnant or breast-feeding or of childbearing potential without the use of adequate contraceptive methods during the length of the study
- Non-responsive to topical prostaglandins, prostamides or prostaglandin analogs
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: OTX-TIC Low Dose
Travoprost Intracameral Implant low dose
|
OTX-TIC implant is injected into the anterior chamber of the eye.
|
Experimental: OTX-TIC High Dose
Travoprost Intracameral Implant high dose
|
OTX-TIC implant is injected into the anterior chamber of the eye.
|
Active Comparator: Durysta
Bimatoprost Intracameral Implant 10 µg
|
Durysta is injected into the anterior chamber of the eye.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy Outcome: IOP changes from Baseline
Time Frame: Diurnal IOP [Time Frame: diurnal IOP at the 2 Week Visit] Diurnal IOP [Time Frame: diurnal IOP at the 6 Week Visit] Diurnal IOP [Time Frame: diurnal IOP at the 12 Week Visit]
|
IOP changes from baseline at 8AM, 10AM, and 4PM at Week 2, Week 6, and Week 12 in the study eye
|
Diurnal IOP [Time Frame: diurnal IOP at the 2 Week Visit] Diurnal IOP [Time Frame: diurnal IOP at the 6 Week Visit] Diurnal IOP [Time Frame: diurnal IOP at the 12 Week Visit]
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 16, 2022
Primary Completion (Estimated)
January 1, 2024
Study Completion (Estimated)
January 1, 2025
Study Registration Dates
First Submitted
April 12, 2022
First Submitted That Met QC Criteria
April 12, 2022
First Posted (Actual)
April 19, 2022
Study Record Updates
Last Update Posted (Estimated)
December 12, 2023
Last Update Submitted That Met QC Criteria
December 11, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OTX-TIC-2020-201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Hypertension
-
Western Galilee Hospital-NahariyaUnknown
-
Laboratoires TheaCompletedOcular Hypertension GlaucomaBulgaria
-
Santen Inc.Completed
-
West Virginia UniversityUniversity of PittsburghRecruitingGlaucoma and Ocular HypertensionUnited States, United Kingdom, Canada
-
University Hospital, GenevaTerminatedGlaucoma and Ocular HypertensionSwitzerland
-
Santen Inc.Completed
-
Maastricht University Medical CenterCompletedCorticosteroid Induced Ocular Hypertension/GlaucomaNetherlands
-
Santen Inc.CompletedA Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTGlaucoma and Ocular HypertensionUnited States
-
Bausch & Lomb IncorporatedCompletedGlaucoma | Open Angle or Ocular HypertensionUnited States
-
Nicox Ophthalmics, Inc.CompletedGlaucoma, Open-Angle | Hypertension, OcularUnited States
Clinical Trials on OTX-TIC low dose Travoprost Intracameral Implant
-
Perfuse Therapeutics, Inc.Recruiting
-
Perfuse Therapeutics, Inc.Recruiting
-
Glaukos CorporationRecruitingOcular Hypertension | Open Angle GlaucomaUnited States
-
Glaukos CorporationCompletedGlaucoma Open-angleUnited States
-
British Columbia Cancer AgencyBC Cancer FoundationRecruiting
-
British Columbia Cancer AgencyRecruitingOligometastatic Prostate CancerCanada
-
CHU de Quebec-Universite LavalRecruiting
-
SpyGlass Pharma, Inc.RecruitingOcular Hypertension | Glaucoma | CataractUnited States